



## **Mycovia Appoints Tiffany Ahlers as Senior Vice President, Commercialization**

*Ahlers to lead commercial initiatives as lead product candidate VT-1161 moves rapidly through clinical development as a potential first FDA-approved treatment of recurrent vulvovaginal candidiasis*

Durham, NC – July 31, 2019 – [Mycovia Pharmaceuticals](#) today announced the appointment of Tiffany Ahlers as Senior Vice President, Commercialization. In this role, Ms. Ahlers will oversee global commercial operations for the company in addition to supporting business development activities and overall company branding.

“Tiffany’s proven record in leading and managing operations for biopharmaceutical companies will be instrumental as we move toward commercialization of VT-1161 for the treatment of recurrent vulvovaginal candidiasis (RVVC), a disease for which there are no approved treatments in the US,” said Patrick Jordan, Chief Executive Officer of Mycovia. “With Tiffany’s 20 years of cross-functional experience in leading commercial strategy, a global Phase 3 program recruiting ahead of schedule, and an exclusive license agreement with Hengrui Medicine to develop and commercialize VT-1161 in China, Mycovia is building global commercial capabilities in anticipation of launching VT-1161 in 2021. We welcome Tiffany to the team and look forward to working with her as we work to scale our organization into a fully integrated biopharmaceutical company.”

“Joining a company that is paving the path for a potential new treatment paradigm for millions of people living with RVVC and other fungal diseases is a tremendous opportunity,” said Ms. Ahlers. “The Phase 2 data clearly demonstrates VT-1161’s profound efficacy in the treatment of RVVC, and I am thrilled to play a role in translating its clinical potential into commercial reality.”

Ms. Ahlers most recently served as a Senior Vice President at Cello Health Advantage, a boutique market research and consultancy firm, that supports the global pharmaceutical, biotech and health sectors. Previously, she spent almost 10 years at Stallergenes Greer, where she served as Vice President of Marketing and led, developed and managed the daily operations for the US marketing department and the company’s business units. Ms. Ahlers also worked at Cornerstone Therapeutics, which is now Chiesi USA.

### **About Mycovia Pharmaceuticals**

Mycovia Pharmaceuticals has a passion for developing breakthrough therapies in areas of unmet medical need, with an initial focus in women’s health. Our lead product candidate, VT-1161 (oteseconazole), is a novel, oral therapy for recurrent vulvovaginal candidiasis (RVVC) that

is designed to have greater selectivity, fewer side effects and improved potency than current treatment options. VT-1161 received FDA Qualified Infectious Disease Product and Fast-Track designations to support its potential as the first FDA-approved treatment for RVVC. Mycovia also recognizes that there is tremendous potential for its oral fungal inhibitors to treat a range of multi-drug resistant fungal pathogens. For more information, please visit [www.mycovia.com](http://www.mycovia.com)

**Contacts**

Mycovia Pharmaceuticals

Stephen Brand, Ph.D., 919-467-8539

[sbrand@mycovia.com](mailto:sbrand@mycovia.com)

**Media**

MacDougall

Lauren Arnold, 781-235-3060

[larnold@macbiocom.com](mailto:larnold@macbiocom.com)